599 C-reactive protein; a potential marker of second cancer and cardiovascular disease in testicular cancer survivors?

2010 ◽  
Vol 8 (5) ◽  
pp. 152-153
Author(s):  
W. Torgeir ◽  
H.S.H. Haugnes ◽  
J. Kjekshus ◽  
M.C.S. Småstuen ◽  
T.T. Ueland ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Testicular Cancer ◽  
Cancer Survivors ◽  
Protein A ◽  
Second Cancer ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Potential Marker ◽  
Testicular Cancer Survivors

Early changes in renal function and late cardiovascular disease risk in testicular cancer survivors with 25 years follow-up.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 4541-4541
Author(s):  
Sjoukje Lubberts ◽  
Joost A.B. Kampman ◽  
Hink Boer ◽  
Coby Meijer ◽  
Gerjan J. Navis ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Renal Function ◽  
Testicular Cancer ◽  
Cancer Survivors ◽  
Disease Risk ◽  
Cardiovascular Disease Risk ◽  
Testicular Cancer Survivors

scholarly journals Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score

2018 ◽  
Vol 16 (4) ◽  
pp. e761-e769 ◽  
Author(s):  
Darren R. Feldman ◽  
Shirin Ardeshir-Rouhani-Fard ◽  
Patrick Monahan ◽  
Howard D. Sesso ◽  
Chunkit Fung ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Testicular Cancer ◽  
Cancer Survivors ◽  
Risk Score ◽  
Framingham Risk Score ◽  
Framingham Risk ◽  
Testicular Cancer Survivors

scholarly journals Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors

2018 ◽  
Vol 2018 ◽  
pp. 1-20 ◽  
Author(s):  
Chunkit Fung ◽  
Paul Dinh ◽  
Shirin Ardeshir-Rouhani-Fard ◽  
Kerry Schaffer ◽  
Sophie D. Fossa ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Testicular Cancer ◽  
Cancer Survivors ◽  
Current Status ◽  
Malignant Neoplasms ◽  
Targeted Prevention ◽  
Care Providers ◽  
National Guidelines ◽  
Testicular Cancer Survivors

Testicular cancer has become the paradigm of adult-onset cancer survivorship, due to the young age at diagnosis and 10-year relative survival of 95%. This clinical review presents the current status of various treatment-related complications experienced by long-term testicular cancer survivors (TCS) free of disease for 5 or more years after primary treatment. Cardiovascular disease and second malignant neoplasms represent the most common potentially life-threatening late effects. Other long-term adverse outcomes include neuro- and ototoxicity, pulmonary complications, nephrotoxicity, hypogonadism, infertility, and avascular necrosis. Future research efforts should focus on delineation of the genetic underpinning of these long-term toxicities to understand their biologic basis and etiopathogenetic pathways, with the goal of developing targeted prevention and intervention strategies to optimize risk-based care and minimize chronic morbidities. In the interim, health care providers should advise TCS to adhere to national guidelines for the management of cardiovascular disease risk factors, as well as to adopt behaviors consistent with a healthy lifestyle, including smoking cessation, a balanced diet, and a moderate to vigorous intensity exercise program. TCS should also follow national guidelines for cancer screening as currently applied to the general population.

Sign in / Sign up

Export Citation Format

Share Document